engleski

Mailed dosimetry auditing in proton therapy - evaluation of RPL detectors in proton therapy beam- EURADOS-WG 9 preliminary results

Proton therapy is advanced and innovative cancer radiotherapy modality for treatment of early and advanced tumors. Today proton therapy has been increasingly used and number of proton radiotherapy centers worldwide is constantly growing. At present 60 proton therapy facilities are in operation, more than 30 are under construction and more than 15 are in planning stage. Around 130000 patients’ worldwide have been treated with protons since the establishment of the first hospital-based treatment center in Loma Linda, California, in 1990. In order to control proper dose delivery to patients as well as part of comprehensive approach to quality assurance (QA) in the treatment of cancer by radiation, independent external dosimetric audits are an important and necessary component to ensure adequate quality of practice and delivery of treatment in radiation oncology. Since 1969 IAEA, together with the World Health Organization (WHO), has performed thermoluminescence dosimetry (TLD) audits by mail to verify the calibration of external radiotherapy beams in radiation therapy departments (or hospitals) in developing countries. Also national programs for mail auditing of radiotherapy centers have been widely implemented. On the other hand dosimetry auditing of proton therapy facilities is still not available in Europe. The hadrontherapy sub-group of EURADOS Working Group 9 (Radiation dosimetry in radiotherapy) started activities towards dosimetry in proton therapy fields. One of the objectives is to build and test a system for auditing proton therapy centers allowing assistance, quality control and harmonization of proton therapy centers in Europe. An important first step for EURADOS WG9 is to perform an intecomparison and full characterization of different solid state detectors in proton fields. Four institutes, IFJ-PAN from Poland, SCK•CEN from Belgium, RBI from Croatia and ISS from Italy are participating in the measurement campaign with different dosimetry systems. The following dosimeters are tested in the IBA (230 MeV) active-scanning proton beam: thermoluminescent (MCP-n and MTS-n), radiophotoluminescent (GD- 352M and GD302-M) optically stimulated (OSL) and alanine. Preliminary results mainly for RPL detectors will be presented.

RPL detectors ; TLD ; mailed dosimetry ; proton radiotherapy

nije evidentirano